Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of NovemberSeeking Alpha • 11/17/25
Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTXBusiness Wire • 11/16/25
Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium TranscriptSeeking Alpha • 11/14/25
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happyMarket Watch • 11/14/25
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics DealInvestors Business Daily • 11/14/25
Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approachesInvezz • 11/14/25
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral AgentBusiness Wire • 11/14/25
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH TrialBusiness Wire • 11/09/25
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%Investors Business Daily • 11/08/25
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids TrialBusiness Wire • 11/08/25
As Merck Stock Gets Back To Its Feet, Here's One Possible Option TradeInvestors Business Daily • 11/06/25
Merck and Blackstone enter research agreement to develop cancer therapy for $700 millionReuters • 11/04/25
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)Business Wire • 11/04/25